Ontogeny of toll-like and NOD-like receptor-mediated innate immune responses in Papua New Guinean infants

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lisciandro, Joanne G ^a,b   Prescott, Susan L ^b   Nadal Sims, Marie G ^a   Devitt, Catherine J ^a   Pomat, William ^c   Siba, Peter M ^c   Tulic, Meri C ^b   Holt, Patrick G ^a   Strickland, Deborah ^a   van den Biggelaar, Anita H J ^a,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; ALUMINUM SULFATE; CARRIER PROTEIN; IL1B PROTEIN, HUMAN; INFLAMMASOME; NLRP3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

AGE; ARTICLE; BLOOD; CHILD; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HUMAN; INFANT; INFLAMMATION; INNATE IMMUNITY; MALE; ONTOGENY; PAPUA NEW GUINEA; VACCINATION; CELL CULTURE; CROSS-SECTIONAL STUDY; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; IMMUNE SYSTEM; METABOLISM; MONONUCLEAR CELL; NONPARAMETRIC TEST; PHYSIOLOGY;

AGE FACTORS; ALUM COMPOUNDS; CARRIER PROTEINS; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; INFANT; INFLAMMASOMES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKIN-6; LEUKOCYTES, MONONUCLEAR; PAPUA NEW GUINEA; STATISTICS, NONPARAMETRIC; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861389479     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036793     Document Type: Article

References (43)

1. Angelone DF, Wessels MR, Coughlin M, Suter EE, Valentini P, et al. (2006) Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatric Research 60: 205-209.
2. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, et al. (2006) The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 177: 1956-1966.
3. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, et al. (2004) Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J Immunol 173: 4627-4634.
4. De Wit D, Tonon S, Olislagers V, Goriely S, Boutriaux M, et al. (2003) Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J Autoimmun 21: 277-281.
5. Adkins B, Bu Y, Vincek V, Guevara P, (2003) The primary responses of murine neonatal lymph node CD4+ cells are Th2-skewed and are sufficient for the development of Th2-biased memory. Clin Dev Immunol 10: 43-51.
6. Goriely S, Vincart B, Stordeur P, Vekemans J, Willems F, et al. (2001) Deficient IL-12(p35) gene expression by dendritic cells derived from neonatal monocytes. J Immunol 166: 2141-2146.
7. Levy O, (2007) Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 7: 379-390.
8. Bryce J, Boschi-Pinto C, Shibuya K, Black RE, (2005) WHO estimates of the causes of death in children. Lancet 365: 1147-1152.
9. Lawn JE, Cousens S, Zupan J, (2005) 4 million neonatal deaths: when? Where? Why? Lancet 365: 891-900.
10. Burl S, Townend J, Njie-Jobe J, Cox M, Adetifa UJ, et al. (2011) Age-dependent maturation of Toll-like receptor-mediated cytokine responses in Gambian infants. PLoS One 6: e18185.
11. Nguyen M, Leuridan E, Zhang T, De Wit D, Willems F, et al. (2010) Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS One 5: e10407.
12. Corbett NP, Blimkie D, Ho KC, Cai B, Sutherland DP, et al. (2010) Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One 5: e15041.
13. Yerkovich ST, Wikstrom ME, Suriyaarachchi D, Prescott SL, Upham JW, et al. (2007) Postnatal development of monocyte cytokine responses to bacterial lipopolysaccharide. Pediatr Res 62: 547-552.
14. Lisciandro JG, van den Biggelaar AH, (2010) Neonatal immune function and inflammatory illnesses in later life: lessons to be learnt from the developing world? Clin Exp Allergy 40: 1719-1731.
15. van den Biggelaar AH, Holt PG, (2010) 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: neonatal immune function and vaccine responses in children born in low-income versus high-income countries. Clin Exp Immunol 160: 42-47.
16. van den Biggelaar AH, Prescott SL, Roponen M, Nadal-Sims MA, Devitt CJ, et al. (2009) Neonatal innate cytokine responses to BCG controlling T-cell development vary between populations. J Allergy Clin Immunol 124: 544-550, 550 e541-542.
17. Lalor MK, Ben-Smith A, Gorak-Stolinska P, Weir RE, Floyd S, et al. (2009) Population differences in immune responses to Bacille Calmette-Guerin vaccination in infancy. J Infect Dis 199: 795-800.
18. Lalor MK, Floyd S, Gorak-Stolinska P, Ben-Smith A, Weir RE, et al. (2011) BCG Vaccination Induces Different Cytokine Profiles Following Infant BCG Vaccination in the UK and Malawi. J Infect Dis 204: 1075-1085.
19. Philbin VJ, Levy O, (2009) Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 65: 98R-105R.
20. Elinav E, Strowig T, Henao-Mejia J, Flavell RA, (2011) Regulation of the antimicrobial response by NLR proteins. Immunity 34: 665-679.
21. Kawai T, Akira S, (2009) The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21: 317-337.
22. Fleer A, Krediet TG, (2007) Innate immunity: toll-like receptors and some more. A brief history, basic organization and relevance for the human newborn. Neonatology 92: 145-157.
23. Li H, Willingham SB, Ting JP, Re F, (2008) Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 181: 17-21.
24. Li H, Nookala S, Re F, (2007) Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178: 5271-5276.
25. Aimanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV, Bayry J, (2009) Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. Trends Pharmacol Sci 30: 287-295.
26. Higgins SC, Mills KH, (2010) TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants. Curr Infect Dis Rep 12: 4-12.
27. Belderbos ME, van Bleek GM, Levy O, Blanken MO, Houben ML, et al. (2009) Skewed pattern of Toll-like receptor 4-mediated cytokine production in human neonatal blood: low LPS-induced IL-12 p 70 and high IL-10 persist throughout the first month of life. Clin Immunol 133: 228-237.
28. Tulic MK, Hodder M, Forsberg A, McCarthy S, Richman T, et al. (2011) Differences in innate immune function between allergic and nonallergic children: New insights into immune ontogeny. J Allergy Clin Immunol 127: 470-478 e471.
29. Prescott SL, Taylor A, King B, Dunstan J, Upham JW, et al. (2003) Neonatal interleukin-12 capacity is associated with variations in allergen-specific immune responses in the neonatal and postnatal periods. Clin Exp Allergy 33: 566-572.
30. Prescott SL, Noakes P, Chow BW, Breckler L, Thornton CA, et al. (2008) Presymptomatic differences in Toll-like receptor function in infants who have allergy. J Allergy Clin Immunol 122: 391-399, 399 e391-395.
31. Mutapi F, Winborn G, Midzi N, Taylor M, Mduluza T, et al. (2007) Cytokine responses to Schistosoma haematobium in a Zimbabwean population: contrasting profiles for IFN-gamma, IL-4, IL-5 and IL-10 with age. BMC Infect Dis 7: 139.
32. van den Biggelaar AH, Pomat W, Bosco A, Phuanukoonnon S, Devitt CJ, et al. (2011) Pneumococcal conjugate vaccination at birth in a high-risk setting: no evidence for neonatal T-cell tolerance. Vaccine 29: 5414-5420.
33. Centers for Disease Control and Prevention (2011) Epidemiology and Prevention of Vaccine-Preventable Diseases; Atkinson W, Wolfe S, Jamborsky J, editors. Washington, eds. D.C.: Public Health Foundation.
34. Centers for Disease Control and Prevention (2010) Global Routine Vaccination Coverage, 2009. Morbidity and Mortality Weekly Report (MMWR) 59: 1367-1371.
35. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA, (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
36. De Gregorio E, D'Oro U, Wack A, (2009) Immunology of TLR-independent vaccine adjuvants. Curr Opin Immunol 21: 339-345.
37. Guarda G, Dostert C, Staehli F, Cabalzar K, Castillo R, et al. (2009) T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460: 269-273.
38. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A, (2010) The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 40: 638-642.
39. Levy O, Suter EE, Miller RL, Wessels MR, (2006) Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108: 1284-1290.
40. Herbert OC, Barnetson RS, Weninger W, Kramer U, Behrendt H, et al. (2009) Western Lifestyle and Increased Prevalence of Atopic Diseases: An example from a Small Papua New Guinean Island. World Allergy Organisation Journal 2: 130-137.
41. Conrad ML, Ferstl R, Teich R, Brand S, Blumer N, et al. (2009) Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwoffii F78. J Exp Med 206: 2869-2877.
42. Roduit C, Wohlgensinger J, Frei R, Bitter S, Bieli C, et al. (2011) Prenatal animal contact and gene expression of innate immunity receptors at birth are associated with atopic dermatitis. J Allergy Clin Immunol 127: 179-185, 185 e171.
43. Blimkie D, Fortuno ES III, Yan H, Cho P, Ho K, et al. (2011) Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation. J Immunol Methods 366: 89-99.